Observational Study With InnoLet® in Daily Clinical Practice

• Status: Completed
• Trial end date: 2005-03-23
• Target enrollment: 0
• Participant gender: All

Summary

This study is conducted in Asia. The aim of this study is to review the efficacy and safety of insulin treatment with InnoLet® in daily clinical practice.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Diabetes mellitus (Type 1 or type 2)

• Need insulin treatment